Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Colfax Corporation in connection with the acquisition of the GCE Group
Mandate

Vinge has advised Colfax Corporation in connection with the acquisition of the GCE Group

August 06, 2018 M&A

GCE is Europe's leading gas equipment company with, inter alia, pressure regulators and welding nozzles in its product portfolio.

The GCE Group headquarters are located in Malmö (Sweden) and the group conducts business in over 15 countries. The main production sites are located in the Czech Republic and China. 

The transaction is subject to approval by relevant competition authorities.

Vinge’s team consisted primarily of Daniel Rosvall, Ulrich Ziche, Peter Issa, Stina Bengtsson, Elisabeth Hallberg, Ludvig Wettergren, Agnes Perbo, Sebastian Frisk, Christina Odengran, Hedvig Ekdahl, Hayaat Ibrahim, Sophia Holm, Sarah Berger, Malin Malm Waerme and Nicklas Thorgerzon.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024